Cargando…

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001

The platelet inhibitory effects of the Phase 3 anticancer agent and nitric oxide (NO) donor, RRx‐001, (1‐bromoacetyl‐3,3‐dinitroazetidine) were examined ex vivo and compared with the diazeniumdiolate NO donor, diethylenetriamine NONOate (DETA‐NONOate), which spontaneously releases nitric oxide in aq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oronsky, Bryan, Oronsky, Neil, Cabrales, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156345/ https://www.ncbi.nlm.nih.gov/pubmed/30010241 http://dx.doi.org/10.1111/jcmm.13791

Ejemplares similares

RRx-001, A novel dinitroazetidine radiosensitizer
por: Oronsky, Bryan, et al.
Publicado: (2016)

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
por: Oronsky, Bryan., et al.
Publicado: (2020)

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria
por: Yalcin, Ozlem, et al.
Publicado: (2015)

RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature
por: Jani, Vinay P., et al.
Publicado: (2021)

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
por: Oronsky, Bryan, et al.
Publicado: (2016)

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
por: Oronsky, Bryan, et al.
Publicado: (2018)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
por: Carter, Corey A., et al.
Publicado: (2015)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)
por: Reid, Tony, et al.
Publicado: (2023)

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
por: Ning, Shoucheng, et al.
Publicado: (2015)

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
por: Zhao, Hongjuan, et al.
Publicado: (2015)

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
por: Zhao, Hongjuan, et al.
Publicado: (2017)

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist
por: Oronsky, Bryan, et al.
Publicado: (2023)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
por: Carter, Corey A., et al.
Publicado: (2016)

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients
por: Reid, T., et al.
Publicado: (2014)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
por: Oronsky, Bryan, et al.
Publicado: (2020)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
por: Carter, Corey A., et al.
Publicado: (2016)

Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats
por: Caroen, Scott, et al.
Publicado: (2022)

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors
por: Raghunand, Natarajan, et al.
Publicado: (2017)

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation
por: Jayabalan, Nanthini, et al.
Publicado: (2023)

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor
por: Brzezniak, Christina, et al.
Publicado: (2017)

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001
por: Oronsky, Bryan, et al.
Publicado: (2016)

Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001
por: Hammond, Terese Catherine, et al.
Publicado: (2022)

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization
por: Carter, Corey A., et al.
Publicado: (2016)

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001()
por: Scicinski, Jan, et al.
Publicado: (2015)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells
por: Das, Deepika Sharma, et al.
Publicado: (2016)

RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice
por: Jurgensen, Kimberly J., et al.
Publicado: (2021)

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit
por: Tomita, Yusuke, et al.
Publicado: (2021)

Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets
por: Ojemuyiwa, Michelle, et al.
Publicado: (2018)

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial()(): A TITE-CRM Phase I/II Clinical Trial
por: Kim, Michelle M., et al.
Publicado: (2016)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
por: Brzezniak, Christina, et al.
Publicado: (2016)

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
por: Cabrales, Pedro
Publicado: (2019)

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
por: Oronsky, Bryan, et al.
Publicado: (2016)

Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
por: Oronsky, Bryan, et al.
Publicado: (2018)

Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
por: Oronsky, Bryan, et al.
Publicado: (2014)

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
por: Oronsky, Bryan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q92jkld0vjs4bhe32bmieq48s5